Eddie Hickman
Stock Analyst at Guggenheim
(4.18)
# 1,455
Out of 4,371 analysts
42
Total ratings
57.9%
Success rate
20.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eddie Hickman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZVRA Zevra Therapeutics | Maintained: Buy | $23 → $25 | $11.17 | +123.81% | 6 | May 8, 2026 | |
| TARS Tarsus Pharmaceuticals | Reiterated: Buy | $90 | $60.34 | +49.15% | 14 | May 7, 2026 | |
| ATAI AtaiBeckley | Reiterated: Buy | $11 → $16 | $4.50 | +255.56% | 2 | Apr 16, 2026 | |
| GHRS GH Research | Maintained: Buy | $29 → $34 | $23.25 | +46.24% | 4 | Mar 9, 2026 | |
| PMN ProMIS Neurosciences | Maintained: Buy | $125 → $35 | $9.73 | +259.71% | 4 | Feb 5, 2026 | |
| HELP Cybin | Maintained: Buy | $39 → $48 | $4.43 | +983.52% | 3 | Dec 3, 2025 | |
| OTLK Outlook Therapeutics | Downgraded: Hold | n/a | $0.7948 | - | 7 | Aug 28, 2025 | |
| IMVT Immunovant | Reiterated: Buy | $44 | $32.67 | +34.68% | 2 | Aug 11, 2025 |
Zevra Therapeutics
May 8, 2026
Maintained: Buy
Price Target: $23 → $25
Current: $11.17
Upside: +123.81%
Tarsus Pharmaceuticals
May 7, 2026
Reiterated: Buy
Price Target: $90
Current: $60.34
Upside: +49.15%
AtaiBeckley
Apr 16, 2026
Reiterated: Buy
Price Target: $11 → $16
Current: $4.50
Upside: +255.56%
GH Research
Mar 9, 2026
Maintained: Buy
Price Target: $29 → $34
Current: $23.25
Upside: +46.24%
ProMIS Neurosciences
Feb 5, 2026
Maintained: Buy
Price Target: $125 → $35
Current: $9.73
Upside: +259.71%
Cybin
Dec 3, 2025
Maintained: Buy
Price Target: $39 → $48
Current: $4.43
Upside: +983.52%
Outlook Therapeutics
Aug 28, 2025
Downgraded: Hold
Price Target: n/a
Current: $0.7948
Upside: -
Immunovant
Aug 11, 2025
Reiterated: Buy
Price Target: $44
Current: $32.67
Upside: +34.68%